Cargando…
Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study
Observational studies suggested inconsistent associations between lipid-lowering drugs, such as statins, and renal cell carcinoma (RCC) risk. In a two-sample Mendelian randomization (MR) framework, we assessed the causal influence of lipid-lowering agents and circulating lipid traits on overall and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545796/ https://www.ncbi.nlm.nih.gov/pubmed/34712689 http://dx.doi.org/10.3389/fnut.2021.755834 |
_version_ | 1784590070054912000 |
---|---|
author | Liu, Luyang Sheng, Chao Lyu, Zhangyan Dai, Hongji Chen, Kexin |
author_facet | Liu, Luyang Sheng, Chao Lyu, Zhangyan Dai, Hongji Chen, Kexin |
author_sort | Liu, Luyang |
collection | PubMed |
description | Observational studies suggested inconsistent associations between lipid-lowering drugs, such as statins, and renal cell carcinoma (RCC) risk. In a two-sample Mendelian randomization (MR) framework, we assessed the causal influence of lipid-lowering agents and circulating lipid traits on overall and sex-specific RCC risk. Genetic variants of six drug-target genes were selected to proxy the effects of low-density lipoprotein cholesterol (LDL-C) lowering therapies. Instrumental variables for circulating lipid traits were constructed from two large genome-wide association studies. We used endpoints for RCC from summary statistics of two studies [International Agency for Research on Cancer [IARC], N = 13,230; National Cancer Institute [NCI], N = 4,735]. The robustness of results was assessed through conventional MR sensitivity analyses. Overall, there was no significant association between genetically proxied HMG-CoA reductase (HMGCR) inhibition and RCC risk [Odds ratio [OR] = 1.42, 95% CI, 0.29–6.99]. In the sex-stratified analysis, we observed a positive association for genetically proxied drug targets with RCC risk. Specifically, genetically proxied proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition was associated with a higher risk of RCC in men [OR = 2.20 [95% CI, 1.24–3.89]], and the difference by sex was moderate. This study suggested genetically proxied inhibition of HMGCR was not associated with RCC risk, while genetically proxied PCSK9 inhibition might be associated with a higher risk of RCC in male. |
format | Online Article Text |
id | pubmed-8545796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85457962021-10-27 Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study Liu, Luyang Sheng, Chao Lyu, Zhangyan Dai, Hongji Chen, Kexin Front Nutr Nutrition Observational studies suggested inconsistent associations between lipid-lowering drugs, such as statins, and renal cell carcinoma (RCC) risk. In a two-sample Mendelian randomization (MR) framework, we assessed the causal influence of lipid-lowering agents and circulating lipid traits on overall and sex-specific RCC risk. Genetic variants of six drug-target genes were selected to proxy the effects of low-density lipoprotein cholesterol (LDL-C) lowering therapies. Instrumental variables for circulating lipid traits were constructed from two large genome-wide association studies. We used endpoints for RCC from summary statistics of two studies [International Agency for Research on Cancer [IARC], N = 13,230; National Cancer Institute [NCI], N = 4,735]. The robustness of results was assessed through conventional MR sensitivity analyses. Overall, there was no significant association between genetically proxied HMG-CoA reductase (HMGCR) inhibition and RCC risk [Odds ratio [OR] = 1.42, 95% CI, 0.29–6.99]. In the sex-stratified analysis, we observed a positive association for genetically proxied drug targets with RCC risk. Specifically, genetically proxied proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition was associated with a higher risk of RCC in men [OR = 2.20 [95% CI, 1.24–3.89]], and the difference by sex was moderate. This study suggested genetically proxied inhibition of HMGCR was not associated with RCC risk, while genetically proxied PCSK9 inhibition might be associated with a higher risk of RCC in male. Frontiers Media S.A. 2021-10-12 /pmc/articles/PMC8545796/ /pubmed/34712689 http://dx.doi.org/10.3389/fnut.2021.755834 Text en Copyright © 2021 Liu, Sheng, Lyu, Dai and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Nutrition Liu, Luyang Sheng, Chao Lyu, Zhangyan Dai, Hongji Chen, Kexin Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study |
title | Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study |
title_full | Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study |
title_fullStr | Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study |
title_full_unstemmed | Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study |
title_short | Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study |
title_sort | association between genetically proxied lipid-lowering drug targets and renal cell carcinoma: a mendelian randomization study |
topic | Nutrition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545796/ https://www.ncbi.nlm.nih.gov/pubmed/34712689 http://dx.doi.org/10.3389/fnut.2021.755834 |
work_keys_str_mv | AT liuluyang associationbetweengeneticallyproxiedlipidloweringdrugtargetsandrenalcellcarcinomaamendelianrandomizationstudy AT shengchao associationbetweengeneticallyproxiedlipidloweringdrugtargetsandrenalcellcarcinomaamendelianrandomizationstudy AT lyuzhangyan associationbetweengeneticallyproxiedlipidloweringdrugtargetsandrenalcellcarcinomaamendelianrandomizationstudy AT daihongji associationbetweengeneticallyproxiedlipidloweringdrugtargetsandrenalcellcarcinomaamendelianrandomizationstudy AT chenkexin associationbetweengeneticallyproxiedlipidloweringdrugtargetsandrenalcellcarcinomaamendelianrandomizationstudy |